Efficacy of administering remimazolam at anesthetic management for awake craniotomy

Efficacy of administering remimazolam at anesthetic management for Asleep-Awake-Asleep method of awake craniotomy;Randomized control study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1041200094

Enrollment

Registered

2021-01-28

Start date

2021-02-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain tumor Brain tumor

Interventions

Setting of remimazolam administration group and propofol administration group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who undergo elective awake craniotomy

Exclusion criteria

Exclusion criteria: 1)Patients who do not agree. 2)have a liver disfunction(Child-pugh classification B or higher). 3)have an allergy for the ropivacaine and other anesthetics drugs. 4)have an obvious hemostatic dysfunction(Platelet count of 80000 or less,PT-INR of 1.5 or more,APTT of 40 seconds or more). 5)have a severe respiratory disorder(%VC<60%,orFEV1%<50%). 6)have a primary closed angle glaucoma 7)have a heart failure (ejection fraction of 45% or less on echocardiography, presence of severe valvular disease, and past history of coronary artery disease). 8)patient who can not be in candidate at this study decided by the doctor

Design outcomes

Primary

Measure	Time frame
Time (second) needed to awake before awake phase.	—

Contacts

Public ContactTakehito Sato

Nagoya university hospital

takesato@med.nagoya-u.ac.jp+81-52-741-2340

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026